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Abstract The article summarizes the results of clinical
trials in the field of cardiovascular medicine, which were
presented during the Hotline Sessions at the annual meet-
ing of the American College of Cardiology in Orlando,
USA, from 28th March to 31st March 2009. The data were
presented by leading experts in the field with relevant
positions within the trials. Unpublished reports should be
considered as preliminary data as the analysis may change
in the final publications. The summaries presented in the
manuscript were generated from the oral presentations and
provide the readers with the comprehensive information on
the results of the latest clinical trials in cardiovascular
medicine.
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NAPLES II (novel approaches for preventing
or limiting event study impact of a single high loading
dose of atorvastatin on periprocedural myocardial
infarction)
The purpose of the NAPLES II study was to assess whether
a single, high (80 mg), loading (within 24 h) dose of
atorvastatin is effective in preventing elevation of bio-
markers of myocardial infarction (MI) following elective
coronary stent implantation. Periprocedural MI was defined
as an elevation of CKMB C3-fold of the upper limit of
normal (non-Q wave MI) or CKMB C2-fold of the upper
limit with new significant Q waves in C2 contiguous leads
(Q wave MI) within 12 h after intervention. It was a pro-
spective, randomized, double-arm, two-center clinical
study in Italy. Altogether, 668 patients were randomized
with 338 patients being assigned to the treatment arm, if
they were not treated with a statin previously (mean LDL
similar in both groups 126–129 mg/dl). The results showed
that atorvastatin reduced the incidence of periprocedural
non-Q wave MI in elective PCI. This cardioprotective
effect seems to be more pronounced in patients with high
CRP level at baseline. Together these results suggest that
the beneficial effects of atorvastatin may result from
pleiotropic anti-inflammatory effects.
ARMYDA-RECAPTURE (atorvastatin for reduction
of myocardial damage during angioplasty)
This study was a prospective, multicenter, randomized,
double-blind trial investigating the efficacy of atorvastatin
reload in patients on chronic statin therapy undergoing PCI.
The primary endpoint was the 30-day incidence of cardiac
death, MI, or target vessel revascularization (TVR).
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Patients with chronic ([30 days) statin therapy and stable
angina or NSTE-ACS undergoing coronary angiography
were included in this study (mean LDL similar in both
placebo and verum groups with 92–93 mg/dl). Acute
atorvastatin bolus 80 mg ? 40 mg 12 h pre-PCI was given
in 177 patients (vs. placebo, n = 175) which resulted in a
significant 48% relative risk reduction of the composite
primary end point at 30 days (MACE criteria) with a
number needed to treat (NNT) of 17 (Fig. 1). The benefit
was largely localized to patients who presented with ACS
(with an 87% risk reduction, NNT = 9). In addition, the
incidence of postprocedural CK-MB and troponin elevation
was significantly reduced. The study indicates that
reloading with a high dose of atorvastatin was associated
with improved clinical outcome in patients on chronic
statin therapy undergoing PCI. Similar to NAPLES II,
rapid LDL-independent cardioprotective effects may be
responsible of this phenomenon. These findings may sup-
port a strategy of routine reload with high dose atorvastatin
early before intervention even in the background of chronic
statin therapy.
ABOARD (angioplasty to blunt the rise of troponin
in acute coronary syndromes randomized
for an immediate or delayed intervention)
The ABOARD study was a multicenter randomized trial to
investigate whether immediate intervention (primary PCI
strategy) is superior to delayed intervention (next day
strategy) in patients with moderate to high-risk (TIMI score
C3) in 352 patients with NSTEMI-ACS. All patients were
on optimal medical therapy with high percentages of
aspirin, clopidogrel, heparin, ACE-inhibitors, b-blockers,
statins. 65% of the patients in both groups additionally
received abciximab. The time to catheterization (radial
access in 84% of the patients) was *1 h for the immediate
group (n = 175) and *20 h (n = 177) for the delayed
group. With respect to clinical endpoints (e.g. MI, death) as
well as with respect to surrogate parameters (e.g. troponin,
CK-MB) there was no difference between both groups.
OMEGA (randomized trial of omega-3 fatty acids
on top of modern therapy after acute myocardial
infarction: the OMEGA-trial)
Omega-3 fatty acids were recommended after myocardial
infarction [10]. In this trial, 1 g omega-3 fatty acids where
tested versus placebo (olive oil) on top of optimal medical
therapy. The primary endpoint was sudden cardiac death.
More than 3,800 patients 3–14 days after acute myocardial
infarction (STEMI or NSTEMI) were included. A sudden
cardiac death rate of 3.5% was assumed which may have
been the reason that no differences were found between
both groups having only 1.5% sudden cardiac death on
average. However, even in the secondary endpoints (total
death, reinfarction, stroke, progression of coronary artery
disease, arrhythmic events) no changes were found. In
contrast to the GISSI-HF findings (in patients with chronic
heart failure) after 4 years of following-up the patients
(published last year) 1-year follow-up may not have been
enough to find differences between treatment groups in the
present study investigating omega-3 fatty acids in patients
with MI.
REVIVAL-3 (prospective, randomized, double-blind,
placebo-controlled trial of erythropoietin in patients
with ST-segment elevation myocardial infarction
undergoing percutaneous coronary intervention)
The objective of this study was to assess the effect of high-
dose erythropoietin in patients with acute ST-elevation
myocardial infarction and EF \ 50% treated with primary
PCI. 138 patients were assigned to two groups. The verum
group received erythropoietin beta (3.3 9 104 U) at the
time of balloon inflation, and after 24 as well as 48 h.
There was no difference in the primary end point of left
ventricular EF after 6 months between both groups. Also
infarct size was not reduced. Most disappointingly, there
was even a trend towards a higher risk of adverse clinical
events (MACCE at 6 months), which should be taken into
account before planning future investigations with this










Fig. 1 ARMYDA-RECAPTURE: atorvastatin reduced the primary
endpoint of 30-day MACE significantly
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EARLY-ACS (early glycoprotein IIb/IIIa inhibition
in non-ST-segment elevation acute coronary syndrome:
a randomized, double-blind, placebo-controlled trial
evaluating the clinical benefits of early front-loaded
eptifibatide in the treatment of patients with
non-ST-segment elevation acute coronary syndromes)
The goal of the study was to compare the effect of two
strategies for eptifibatide administration in high-risk NSTE
ACS patients managed with an invasive diagnostic
assessment. The first strategy was a routine, early admin-
istration of eptifibatide to all patients shortly after presen-
tation. The second strategy consisted of a delayed,
provisional eptifibatide administration at the physician’s
discretion after coronary angiography and prior to PCI. In
all five continents [9,400 patients were assigned to this
study. Early eptifibatide compared with delayed, provi-
sional eptifibatide at PCI did not significantly reduce the
primary composite of death, MI, recurrent ischemia
requiring urgent revascularization, or thrombotic bailout at
96 h, but resulted in a trend toward reduction in death or
MI at 30 days with no difference in 30-day mortality. Also,
it resulted in higher rates of non-life-threatening bleeding
and transfusions. Although the results of EARLY-ACS do
not support a strategy of routine early eptifibatide use in
high-risk NSTE ACS patients managed with an invasive
strategy it is possible that a subgroup of patients who have
a low risk of bleeding may be considered for early eptifi-
batide use [4].
TIPS (The Indian Polycap Study)
This randomized and double blind study investigated the
effects of a polypill (Polycap) containing three blood pres-
sure lowering drugs at low doses (thiazide 12.5 mg, atenolol
50 mg, ramipril 5 mg) with and without aspirin (100 mg)
and simvastatin (20 mg). 400 patients with at least one
cardiovascular risk factor in India were randomized to this
group and 200 patients were assigned to eight other groups
(1: aspirin, 2: thiazide, 3: thiazide ? ramipril, 4: thia-
zide ? atenolol, 5: ramipril ? atenolol, 6: thiazide ?
ramipril ? atenolol, 7: thiazide ? ramipril ? atenolol ?
aspirin, 8: simvastatin). Mean heart rate before the study was
80 bpm, systolic RR was 134 mmHg, and LDL was
3.0 mmol/l. After 12 weeks the results clearly showed that
RR was lowered linearly when increasing the number of RR
lowering drugs up to 7 mmHg, heart rate was reduced in all
atenolol groups by 7 bpm. LDL was reduced similarly in the
simvastatin formulations compared to the Polycap group
between 0.7 and 0.83 mmol/l. It was estimated that the
combination of all effects tested using the Polycap could
reduce the relative risk for CHD by 62% and for stroke by
48%. It is concluded by the authors that in patients with
average risk factor levels, the Polycap consisting of five
different cardiovascular drugs has similar effects than the
combination of each of the single drugs, it is well tolerated,
and most importantly it may potentially reduce CVD risk by
about half [1].
ENCORE (cardiovascular benefits associated
with the DASH diet alone and in combination
with exercise and weight reduction in men
and women with high blood pressure)
Cardiovascular risk is influenced by changes in habits [13].
The objective of this study was to examine the effects of
(1) the DASH diet (1,962 kcal) and (2) the DASH diet plus
exercise and weight loss (1,648 kcal) on blood pressure in
overweight patients with high blood pressure. About 150
patients were included in the study. The study showed that
the DASH diet alone resulted in significant blood pressure
lowering (by 11 mmHg systolic blood pressure). However,
exercise and weight loss in addition to the DASH diet
resulted in an incremental decrease in blood pressure (by
16 mmHg systolic blood pressure), as well as greater
improvements in cardiovascular manifestations of high
blood pressure.
Home health monitoring reduces cardiovascular disease
risk in medically underserved communities
The objective was to lower cardiovascular disease risk in
urban and rural underserved communities and to compare
a nurse management program (four visits in 1 year)
versus nurse management plus weekly reporting of CVD
risk factors via telemedicine. Almost 400 subjects with-
out CVD but an increased were included and divided into
the two arms. The primary end point was a reduction in
5% or greater in CVD risk at 1 year. Although this
endpoint was not reached, at least blood pressure was
reduced to a greater extent in the telemedicine group. As
compared to Caucasians, African Americans showed less
blood pressure and lipid control. The authors concluded
that a nurse management program can reduce CVD risk
in medically underserved communities. Telemedicine
provides additional benefit for blood pressure manage-
ment. Male and female subjects achieved similar
improvements in blood pressure and lipids. White sub-
jects achieve lower blood pressure and lipid values
compared to African Americans.
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AURORA (effect of rosuvastatin versus placebo
on cardiovascular outcomes in patients
with end-stage renal disease on hemodialysis)
This study showed that initiation of rosuvastatin did not
cause a reduction in the combined endpoint of CV death,
MI or stroke, even though LDL-C was significantly
reduced and even a minor reduction in Hs-CRP occurred.
Rosuvastatin treatment was well tolerated. The authors
concluded that a lack of CV benefit with statins in both
AURORA and 4D suggests that CVD in hemodialysis
patients is different compared with that in a non-renal
population. There is a need for further research and anal-
ysis of data and to explore new approaches and treatment
strategies for reduction of the high risk of CVD in he-
modialysis patients as stated in the published article by the
authors the same day [3].
JUPITER (CRP reduction, LDL reduction,
and cardiovascular event rates after initiation
of rosuvastatin)
To answer the question, whether the effects of the JUPI-
TER trial (20 mg rosuvastatin in healthy subjects) for the
Prevention of Cardiovascular Events published last year
(44% risk reduction) where due to a reduction of LDL or
CRP, this analysis was presented (Table 1). Among
apparently healthy men and women initiating rosuvastatin
therapy in the JUPITER trial, achieving low target levels of
both LDLC and hsCRP was associated with significantly
improved event-free survival compared with achieving
neither target or with achieving a low LDLC alone. Similar
effects were observed after adjustment for all available
baseline clinical characteristics including entry levels of
LDLC and hsCRP, and in analyses based upon ApoB or the
ApoB:ApoA ratio rather than upon LDLC. A 79% reduc-
tion in risk was observed among those who achieved LDLC
\ 70 mg/dl and the even more aggressive target of
hsCRP \ 1 mg/l [3].
STICH: surgical treatment for ischemic heart failure
trial—CABG versus CABG 1 SVR – hypothesis 2
In the STICH-trial, 1,000 patients with ischemic heart
failure (EF B 35%) and regional anterior-apical left ven-
tricular dysfunction were randomized to CABG (499
patients) or CABG ? SVR (501 patients). Median age was
62 years with no significant differences in baseline char-
acteristics in both treatment groups despite time of surgery.
30 day as well as 5-year cardiovascular mortality was not
different between CABG and CABG ? SVR. The primary
endpoint (death or hospitalization for cardiac causes) was
also not different (CABG 58%, CABG ? SVR 59%, n.s.,
Fig. 2). In both treatment groups, the CCS, NYHA-classi-
fication and the 6-min walking test improved to the same
extent despite end-systolic volume index (20 vs. 3% in
CABG alone), which improved in SVR. Thus additional
SVR-surgery is not beneficial in patients with ischemic
heart failure [6].
FIX-HF-5: multicenter randomized controlled trials
of cardiac contractility modulation in patients
with advanced heart failure
Patients with advanced heart failure with a functional
NYHA-class III-IV and a EF B 35% were enrolled in the
FIX-HF-5-trial to evaluate the influence of an implanted
electrical cardiac contractility modulation (CCM) device
on anaerobic threshold and quality of life. The signals of
the CCM-device are non-excitatory delivered during the
absolute refractory period only to improve cardiac con-
tractility [2]. The safety endpoint of mortality and hospi-
talization after 12 months was not different in both groups
(medical treatment: 213 patients; medical treatment
?CCM: 215 patients). Moreover the primary efficacy
endpoint (anearobic threshold, AT) could not be improved
significantly by CCM compared to medical treatment
alone. However, quality of life, NYHA-classification and
peak VO2 significantly increased in patients with CCM
compared to medical treatment alone. Moreover, a sub-
group-analysis revealed a significant benefit regarding the
primary endpoint of AT in patients with an EF B 25%, but
as a major limitation, there was no blinding in this trial.
Table 1 Hazard ratios for cardiovascular events related to LDL-










hs-CRP levels \2 mg/l
C70 and C2 31/1384 1.11 1.06 (0.72–1.55)
C70 and \2 8/726 0.54 0.42 (0.18–0.94)
\70 and C2 41/2921 0.62 0.53 (0.38–0.74)
\70 and 2 23/2685 0.38 0.35 (0.23–0.54)
C70 or C2 80/5031 0.38 0.64 (0.49–0.84)
hs-CRP levels \1 mg/l
C70 and C1 36/1874 0.95 0.89 (0.62–1.28)
C70 and \1 3/236 0.64 0.46 (0.11–1.85)
\70 and C1 59/4662 0.56 0.49 (0.37–0.66)
\70 and \1 5/944 0.24 0.21 (0.09–0.51)
C70 or C1 98/6772 0.67 0.59 (0.46–0.75)
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Pre-RELAX-AHF-Study: relaxin, a novel treatment
for acute heart failure
Relaxin is a natural human peptide, mediating vasoregu-
latory effects especially during pregnancy [9]. In this trials
234 patients with acute heart failure (dyspnoea, congestion
on chest radiograph, and increased brain natriuretic peptide
(BNP) with a normal blood pressure ([125 mmHg) were
assigned to placebo (n = 62) or relaxin 10 lg/kg (n = 40),
30 lg/kg (n = 43), 100 lg/kg (n = 39), or 250 lg/kg
(n = 50) per day. Mean time of enrollment was 6 h with a
treatment period of 48 h. Blood pressure reduction was not
significantly different from placebo in all relaxin treatment
groups in patients with a systolic blood pressure below
140 mmHg at baseline. In patients with an initial systolic
blood pressure above 140 mmHg, there was a significant
reduction by relaxin. Clinical endpoints as dyspnea and
reduction of edema improved with relaxin 30 lg/kg com-
pared to placebo. Length of hospital stay was reduced in
relaxin-treated patients (10.2 ± 6.1 days) compared to
placebo (12.0 ± 7.3 days). Cardiovascular death and days
alive out of hospital were significantly reduced for 30 lg/
kg at days 60 and 180. There were no differences of
adverse or serious adverse events in all treatment groups.
Moreover, renal function was not affected by relaxin
treatment. These results demonstrate the safety of relaxin-
treatment in acute heart failure and are the basis for further
clinical trials [12].
PRIMA-study: can pro-brain natriuretic peptide
guided therapy of heart failure improve heart failure
morbidity and mortality?
Patients with chronic heart failure were managed with a
fixed NT-proBNP level in most trials, but many patients fail
to reach this target [8]. The PRIMA-study investigated,
whether individually management of chronic heart failure
by pro-BNP levels improves morbidity and mortality.
Inclusion criteria were admission to hospital with symp-
tomatic heart failure and an increased NT-proBNP of at least
200 pmol/l. The NT-proBNP guided group (n = 174) was
managed individually with regard to the lowest NT-proBNP
level in the first 2 weeks after beginning of treatment of
acute HF, whereas the clinical judgement group (n = 171)
was not. Within a median FU of 702 days, there was no
statistical difference either in the primary endpoint (days
alive outside hospital, 685 days for BNP group, 664 days for
control) or in cardiovascular mortality or hospitalizations.
Total mortality was 26.5% in the BNP-guided patients and
33.3% in clinically guided patients. However, NT-proBNP
guided management resulted in significantly more frequent
start or increase of heart failure medications.
HORIZONS-AMI-trial: predictors of stent thrombosis
after primary angioplasty in acute myocardial
infarction
The new analysis of the HORIZONS-AMI trial evaluated
risk factors for late stent thrombosis (up to 1 year) after
primary PCI in ST-elevation myocardial infarction in 3,202
patients treated with stenting [11]. Stent thrombosis
occurred in 3.3% of patients (0.9% acute, 1.6% subacute,
1.0% late). There was no difference of rate of stent
thrombosis in patients treated with a drug-eluting or a bare-
metal stent respectively. Risk factors for late stent throm-
bosis were insulin treated diabetes, ongoing smoking, high
number of stents, treatment of ulcerated lesions and total
occlusion of the coronary artery responsible for MI.
Moreover, there was no statistically different rate of stent-
thrombosis in patients receiving bivalirudin (3.6%) com-
pared to heparin and GP IIb/IIIa-inhibitor (3.2%).
High-dose clopidogrel (600 mg) was found to be protective,
especially for subacute stent-thrombosis.
JUPITER: a randomized trial of rosuvastatin
in the prevention of venous thromboembolism
The use of statins might be beneficial not only in arterial,
but also venous disorders. Venous thromboembolism
(VTE) was a secondary endpoint in the JUPITER-trial
evaluating the effect of rosuvastatin in primary prevention
in 17,802 patients [7]. Within a median follow-up of about
2 years, there was a significant reduction of VTEs in the
rosuvastatin group (34 events) compared to placebo (60
events, RRR 43%, p = 0.007, Fig. 3). This result was


































Fig. 2 Kaplan–Meier estimates of the rate of hypothesis 2 primary
endpoints of death or cardiac hospitalization
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provoked events (n = 44, cancer, hospitalization, surgery,
trauma). 93% of VTEs occured before a cardiovascular
event without a significant difference between estimated
relative hazard of VTE (0.57) and primary cardiovascular
(0.56) as a first event. The benefit of decreased rates of
VTEs was consistent within all subgroups.
Eprotirome as a novel and physiological approach
to CVD risk reduction: beneficial effects
on lipoprotein levels when added to statin therapy
Lipid metabolism regulated by thyroid hormones takes place
in the liver. Eprotirome is a liver-selective thyroid receptor
agonist and was evaluated for safety and lipid-lowering
effects combined with a statin in 189 patients with hyper-
cholesterolemia [5]. All lipid markers, especially LDL
(-25%), triglycerides and lipoprotein(a) (both -30 to
-40%) were significantly reduced with eprotirome. Non-
high-density lipoproteins and apolipoprotein B were reduced
by 25%. Thus the substance might be beneficial in patients
who need further LDL-reduction beyond statin treatment or
with a mixed hypercholesterolemia respectively. Within the
trials, eprotirome was safe and function restricted to the liver.
Signs of subclinical coronary atherosclerosis measured
as coronary artery calcification improve risk prediction
of hard events beyond traditional risk factors
in an unselected general population: the Heinz
Nixdorf recall study 5-year outcome data
The prospective cohort-study evaluated more than 4,800
patients without known coronary artery disease for pre-
dictors and signs of subclinical atherosclerosis. The 5-year
outcome data were herein presented with the coronary
artery calcium score (measured by electron-beam tomog-
raphy) being a better predictor of cardiovascular disease
compared to classic risk factors. However, the risk pre-
diction was more valid in men than in women and is
suggested to improve risk prediction of patients, especially
with intermediate risk.
Treatment of intermittent claudication
with hypoxia-inducible factor-1a
Two hundred and eighty-nine patients with claudication
and PAD in both legs (67 years, mean ABI 0.6 in the index
leg) were randomized to three different doses of hypoxia-
inducible factor (HIF)-1a or placebo administered to the
thigh and calf muscle. After 3 and 6 months follow-up
neither peak walking time, walking distance, claudication
onset time nor ABI could be improved. Thus, gene therapy
with HIF-1a offers no benefit in for PAD.
ACTIVE A: clopidogrel plus aspirin versus aspirin
alone for prevention of vascular events in patients
with atrial fibrillation at high risk of stroke
In this trial, 7,554 patients with atrial fibrillation and a high
risk of stroke for whom vitamin K-antagonist were
unsuitable were randomized to aspirin or the combination
of aspirin and clopidogrel (75 mg). Median follow-up was
3.6 years with a relative risk reduction of major vascular
events in the combination group of 11% (p = 0.01). This
result was mainly due to a reduction of stroke (combination

































8,901 8,648 8,447 6,575 3,927 1,986 1,376 1,003 548 161
8,901 8,652 8,417 6,574 3,943 2,012 1,381 993 556 182
HR 0.57, 95%CI 0.37-0.86
P= 0.007
Placebo 60 / 8901
Rosuvastatin 34 / 8901
Fig. 3 Cumulative incidence of
venous thromboembolism in the
JUPITER-trial
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2.4% per year vs. aspirin 3.3% per year, p \ 0.001, Fig. 4).
Rate of myocardial infarction was not statistically signifi-
cant different (combination 0.7% per year vs. aspirin 0.9%
per year, p = 0.08). In contrast, major bleeding was more
common in the combination treatment group (2.0% per
year) compared to aspirin alone (1.3% per year,
p \ 0.001). Thus, the combination of clopidogrel and
aspirin in patients with atrial fibrillation and a high risk of
stroke reduces the rate of stroke, but increases major
hemorrhage.
Cardiac resynchronization therapy prevents disease
progression in NYHA class I-II heart failure patients:
24 months results from the european cohort of the
REVERSE trial
The results of this trial represent the data of the 262
European participants of the REVERSE-trial with 180
patients in the verum-group with enabled CRT function
compared to 82 patients with disabled device function.
After a follow-up of 24 months, patients with enabled
devices had a reduced LVESV (69.7 vs. 94.5 ml/m2,
p \ 0.0001) and LVEDV (103 vs. 132 ml/m2, p \ 0.0001).
In contrast to the 12 months follow-up results, clinical
worsening was significantly less frequent in CRT-patients
(19%) compared to non-CRT patients (34%, p \ 0.01).
Moreover, there was a 62% RRR in time to first hospital-
ization or death in patients with enabled CRT-device.
However, the primary end-point composite of all-cause
mortality, heart-failure hospitalizations, crossover due to
worsening heart failure, NYHA class, and the patient glo-
bal assessment was not significantly different in both
treatment groups. This is most likely to the missing change
of functional parameters, including the Minnesota Living
with Heart Failure Questionnaire, the 6-min walk test, and
NYHA class.
ADMIRE-HF-trial: prognostic significance
of 123I-mIBG myocardial scintigraphy in heart
failure patients
123I meta-iodobenzylguanidine is a physiologic analogue
of norepinephrine, taken up into sympathetic nerves. Due
to prior single centre trials, a lower uptake of 123I mIBG in
patients with heart failure is associated with a poor out-
come. In this trial, 964 patients with chronic heart failure in
a functional NYHA-class II-III were quantified regarding
cardiac uptake of the tracer. The heart/mediastinum-ratio
(H/M) was determined with a cut-off of 1.6 for a high-
uptake. After a follow-up for a maximum of 2 years, the
composite endpoint of NYHA-class progression, poten-
tially life-threatening arrhythmic event and cardiac death
was significantly more frequent in patients with a low
uptake (37%) of the tracer (high-uptake 15%). Moreover,
there were 51 cardiac deaths in the low-uptake and only
two cardiac deaths in the high-uptake group with a negative
predictive value of 98.8% for cardiac death in patients with
a high uptake. Thus, myocardial scintigraphy might be a
useful tool in risk stratification of patients with chronic
heart failure.
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